目的 观察木香顺气丸联合莫沙必利治疗便秘型肠易激综合征的疗效及安全性。方法 选取2013年2月—2015年2月在辽宁省人民医院消化内科就诊的便秘型肠易激综合征患者148例,随机分为治疗组和对照组,每组各74例。对照组单用枸橼酸莫沙必利分散片,5 mg/次,3次/d。治疗组用枸橼酸莫沙必利分散片5 mg/次,3次/d,木香顺气丸6 g/次,3次/d,均餐前30 min服用。两组疗程均为4周。比较了两组症状改善情况、SF-36生活质量、临床疗效及不良反应。结果 治疗后,两组单项症状评分与治疗前比较差异均具有统计学意义(P <0.01、0.05)。治疗组在腹痛或不适、腹胀、排便频率、大便性状、排便异常(排便困难、排便不尽感)及精神问题方面症状改善明显优于对照组(P <0.05)。治疗后,两组症状总积分均明显降低(P <0.01、0.05),两组症状总积分比较差异具有统计学意义(P <0.05)。治疗后各类肠易激综合征患者的SF-36生活质量得分均高于对照组,其中躯体疼痛、总体健康、活力、社会功能、情感职能和精神健康维度的治疗后积分与对照组比较差异具有统计学意义(P <0.05)。治疗后,治疗组总有效率为94.59%,对照组总有效率为83.78%,总有效率组间比较差异具有统计学意义(P <0.05)。两组患者在治疗前后未发现药物相关不良反应。结论 木香顺气丸联合莫沙必利治疗便秘型肠易激综合征可有效改善临床症状,提高生活质量,且具有良好的安全性,具有一定的临床推广价值。

Objective To investigate the effect and safety of Muxiang Shunqi Pills combined with mosapride in treatment of constipation-predominant irritable bowel syndrome. Methods Patients (148 cases) with constipation-predominant irritable bowel syndrome from Department of Gastroenterology in The People's Hospital of Liaoning Province from February 2013 to February 2015 were randomly divided into control and treatment groups. Each group had 74 cases. Patients in control group were singly po administered with Mosapride Citrate Dispersible Tablets, 5 mg/time, three times daily. Patients in treatment group were po administered with Mosapride Citrate Dispersible Tablets, 5 mg/time, three times daily. At the same time, Muxiang Shunqi Pills were given 30 min before meals, 6 g/time, three times daily. Two groups were treated for four weeks. Symptoms improvement, SF-36 life quality, clinical effect, and adverse reactions in two groups were compared. Results After treatment, the symptom scores in the two groups had statistically significant difference, and the difference was statistically significant in the same group (P < 0.05, 0.01). Abdominal pain or discomfort, abdominal distension, defecation frequency, stool traits, abnormal defecation (defecation difficulties and defecation), and mental symptoms of treatment group significantly improved better than those in the control group, with significant differences between two groups (P < 0.05). After treatment, the total scores in two groups were significantly reduced, and the difference was statistically significant in two groups (P < 0.05). After treatment, SF-36 life quality scores in the treatment group were higher than those of control group, and bodily pain, general health, vitality, social functioning, role-emotional, and mental health of treatment group significantly improved better than those in the control group, with significant differences between two groups (P < 0.05). After treatment, the efficacies in the control and treatment groups were 83.78% and 94.59%, respectively, and there were differences between two groups (P < 0.05). There were no adverse reactions in the two groups. Conclusion Muxiang Shunqi Pills combined with mosapride in treatment of constipation-predominant irritable bowel syndrome can improve clinical effect and quality of life, and has good safety, which has a certain clinical application value.